Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fernandez

Showing results (611-620 of 645) with videos related to

Pageof 65
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2007
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina, Karen Marder, Hubert H Fernandez, et al.
Archives of Neurology|March 10, 2010
Increased melanoma risk in Parkinson disease: a prospective clinicopathological studyJohn M Bertoni, John Philip Arlette, Hubert H Fernandez, et al.
Annals of Neurology|November 16, 2011
Solvent exposures and Parkinson disease risk in twinsSamuel M Goldman, Patricia J Quinlan, G Webster Ross, et al.
Environmental Toxicology and Chemistry|October 4, 2021
Trace Metal Residues in Marine Mussels: A Global SurveyMaximiliano Cledon, Louis A Tremblay, Charles Griffiths, et al.
Annals of Neurology|March 17, 2009
Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trialMichael S Okun, Hubert H Fernandez, Samuel S Wu, et al.
Neurology and Therapy|April 1, 2024
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington DiseaseSamuel Frank, Karen E Anderson, Hubert H Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2017
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trialsAlberto J Espay, Michael A Schwarzschild, Caroline M Tanner, et al.
Neurology|April 28, 2017
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD studyHubert H Fernandez, Stewart A Factor, Robert A Hauser, et al.
JAMA Neurology|March 20, 2026
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical TrialHubert H Fernandez, Stuart H Isaacson, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's diseaseHubert H Fernandez, James T Boyd, Victor S C Fung, et al.
Pageof 65

Showing results (611-620 of 645) with videos related to

Sort By:
Pageof 65
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2007
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina, Karen Marder, Hubert H Fernandez, et al.
Archives of Neurology|March 10, 2010
Increased melanoma risk in Parkinson disease: a prospective clinicopathological studyJohn M Bertoni, John Philip Arlette, Hubert H Fernandez, et al.
Annals of Neurology|November 16, 2011
Solvent exposures and Parkinson disease risk in twinsSamuel M Goldman, Patricia J Quinlan, G Webster Ross, et al.
Environmental Toxicology and Chemistry|October 4, 2021
Trace Metal Residues in Marine Mussels: A Global SurveyMaximiliano Cledon, Louis A Tremblay, Charles Griffiths, et al.
Annals of Neurology|March 17, 2009
Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trialMichael S Okun, Hubert H Fernandez, Samuel S Wu, et al.
Neurology and Therapy|April 1, 2024
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington DiseaseSamuel Frank, Karen E Anderson, Hubert H Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2017
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trialsAlberto J Espay, Michael A Schwarzschild, Caroline M Tanner, et al.
Neurology|April 28, 2017
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD studyHubert H Fernandez, Stewart A Factor, Robert A Hauser, et al.
JAMA Neurology|March 20, 2026
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical TrialHubert H Fernandez, Stuart H Isaacson, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's diseaseHubert H Fernandez, James T Boyd, Victor S C Fung, et al.
Pageof 65